Schizophrenia Clinical Trial
Official title:
Personalized and Scalable Cognitive Remediation Approaches
The purpose of this study is to develop and pilot test personalized and scalable approaches to Cognitive Remediation (CR) for schizophrenia and schizoaffective disorder. The intent is to more clearly define the therapeutic targets important to the facilitation of cognitive and functional improvement so that clinicians know how to customize cognitive interventions and deliver treatment in a more effective, efficient and personally relevant manner.
There are three phases of this study.
Phase 1: Development and Adaptation. The goal of this phase is to adapt currently used
computer based CR approaches to make them more personalized and scalable. We will create two
CR interventions which differ in choice and pacing of the cognitive exercises. This phase is
complete.
Phase 2: Open Trial and Intervention Refinement. The goal of this phase is to obtain
quantitative and qualitative feedback on the acceptability and usability of the interventions
from participants to inform further refinement of the assessment and treatment packages. We
will recruit ten subjects from an outpatient psychiatric rehabilitation program in New York
City. After determining study eligibility, individuals will complete a standardized
neuropsychological battery for schizophrenia assessment, and a 5-minute Tone Matching Test to
assess basic auditory processing. Participants will be randomly assigned to receive one of
two intervention packages, developed in Phase 1. Each session includes 60 minutes of
computer-based learning activities and a 15 minute therapist-led discussion that links the
computer activities to cognition as applied to daily tasks and recovery goals. Participants
will complete a total of 10 sessions attending 2-3 times weekly for 5 weeks. During each
session, participants will be asked to keep a log of software used. At the conclusion of this
abbreviated trial, the participants will participate in focus groups in which they will be
asked to provide verbal feedback on how enjoyable, engaging, and useful they perceived the
computer and discussion based exercises to be. Participants will be asked to provide verbal
feedback on the assessment procedures. CR clinicians will join the research team to discuss
participants' engagement and their experience with administering the Tone Matching Test and
interventions. Qualitative data summarized from participant logs and focus groups will be
considered by the research team to refine the assessment battery, treatment parameters, and
rubric of learning exercises. This phase is complete.
Phase 3: Pilot Feasibility Trial. People with a diagnosis of schizophrenia or schizoaffective
disorder may be referred by their treating clinician or may respond to posted advertisements
to inquire about study participation. After being informed of study procedures, interested
individuals will be asked to sign a consent form that documents willingness to participate in
this study. Following informed consent, participants will be asked questions about
demographic characteristics (e.g. age, education, employment), medication and psychosocial
treatment status, psychiatric symptoms and symptoms severity, and will complete a brief
assessment of estimated Intelligence. Those with an Intelligence Quotient (IQ) estimate below
70 or meeting substance dependence criteria at the time of evaluation will be exited from the
study. In the same or second assessment session, participants will complete assessments of
neuropsychological ability, current functioning, and motivation for treatment. Participants
will then be randomly assigned to one of two treatment conditions named "Brain Basics" or
"Brain Exercises".
Each treatment condition is structured in a group format of up to 5 participants. Both
treatments use commercially available computer-based training software to exercise cognitive
skills such as speed of processing, attention, working memory, and verbal memory. Both
conditions will entail 50 minutes on the computer and 10 minutes group discussion. In the
discussion, participants review the cognitive activities they are working on and how they
will help them achieve their recovery goals. The treatment phase will consist of 30 separate
sessions each 60 minutes in duration, administered 3 times a week over the course of a
10-week period. Participants will be re-tested on outcome measures approximately 1 week
following end of treatment, and again 3 months later.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |